Clinical Spotlight

Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020

25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)

Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2  clinical study of TLX101 (also known as 131I-IPA or 4-L-[131I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme (GBM).

 

Telix Pharmaceuticals Limited, ASCO Poster 2020, IPAX-1 Phase ½ Clinical Trial for the treatment of Glioblastoma Brain Cancer

The IPAX-1 poster will present an overview of the study, which is evaluating the safety, dosing schedule and preliminary efficacy of TLX101 in combination with external radiation therapy as a novel treatment approach for patients with recurrent GBM.

“We are grateful to the investigators, site staff, patients and their families and carers who are involved in the IPAX-1 study,” said Dr. Rosalind Wilson, Global Head of Drug Development, Telix Pharmaceuticals. “Telix is committed to researching the potential of molecularly-targeted radiation to address the important unmet medical need of patients who suffer from this terrible disease.”

Details of the presentation are as follows:

Title: IPAX-1: Phase I/II study of 131I-iodo-phenylalanine combined with external radiation therapy as treatment for patients with glioblastoma multiforme

Abstract Number:        TPS2578

Poster Number:            69

Presenting Author:      Josef Pichler, MD

Session:                           Central Nervous System Tumors

The poster will be available on demand by accessing the ASCO Meeting Library beginning Friday, May 29 at 8:00 am EDT.

More Articles

ASX News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...

ASX News

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...

ASX News

FDA Grants Orphan Drug Designation for TLX102

Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...

ASX News

Half Year Shareholder Update

Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update

ASX News

First patient dosed in renal cancer imaging study in Japan

Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...

ASX News

Telix H1 2020 Results and Company Update Conference Call

Melbourne (Australia) – 11th August 2020. Telix will hold an investor conference call to present the Company’s H1 2020 financial...

ASX News

Drug Master File for Glioblastoma Therapy Product Filed with FDA

Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...

ASX News

Activities Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th...

ASX News

Telix Pharmaceuticals Receives $11.4M R&D Tax Refund

Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...

ASX News

Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers

Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical

ASX News

Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product

Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...

Corporate Spotlight

Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020

25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)